Clinical Trial Update: Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) [Phase 2]

View source ↗

Summary

Phase 2 trial of Sunvozertinib (DZD9008) in pretreated non-small cell lung cancer patients with EGFR Exon 20 insertion; the study Wu-Kong6 is currently active a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING